Skip to main content
Article thumbnail
Location of Repository

An investigation into minichromosomal maintenance proteins (MCMs) for the diagnosis of prostate cancer, as a possible alternative to prostate specific antigen (PSA)

By Jane Louise Watkins


The current strategy for the diagnosis of prostate cancer includes serum prostate specific antigen (PSA) measurement. There is however debate into its specificity and sensitivity, so new diagnostic markers are under investigation. Minichromosomal maintenance proteins (MCMs) are potential markers for the diagnosis of neoplasia, as they are involved in cellular replication. The aim of this study is to assess MCM2, 5 and 7 as new diagnostic markers for prostate cancer, to compare the clinical usefulness of PSA and to develop a less invasive technique for diagnosis. PSA specificity was investigated in several human cellular lines, and a clinical study was performed to assess expression in prostatic tissue and blood serum. MCM2, 5 and 7 was investigated by translational and transcriptional means in two prostate cell lines PNT1A and PC-3. In addition, a clinical study was performed to assess the expression of MCM2, 5 and 7 in prostate tissue, urine and blood The results suggest that PSA is not prostate specific, as it is synthesised and secreted by several non-prostatic cell lines. In addition PSA testing does not conclusively indicate neoplastic tissue and serum testing only has 63% sensitivity and 60% specificity in accurately identifying prostate cancer. The in vitro results suggest that the PC-3 cells express less MCM2, 5 and 7 on both the protein and mRNA level compared to the PNT1A cells, suggesting that MCM2, 5 and 7 maybe performing a bigger role than just replication of DNA. The tissue results indicate that there is an increase in MCM2, 5 and 7 epithelial nuclei staining for neoplastic condition compared to BPH. While the clinical study on urine sediment indicates increased MCM2, 5 and 7 staining in prostatic neoplasia compared to BPH and the transcriptional study on MCM5 can identify neoplastic tissue from BPH as 11/12 cancerous patients expressed MCM5 compared to only 3/23 BPH patients. Finally the transcriptional study on the blood samples is inconclusive and need to be repeated These results suggest that serum PSA testing is not ideal for the diagnosis of prostate cancer, that MCM2, 5 and 7 appear to have potential as new diagnostic markers and may aid the histopathologist to allocate Gleason score. Also the MCMs may have potential in the development of a less invasive technique through the use of urine sediment

Publisher: Instiute of Biomedical Science
Year: 2005
OAI identifier:
Provided by: Cranfield CERES

Suggested articles


  1. (raw data shown in Appendix E table e.1 and e.2). Error bar shows the 95% confidence limit for each graph. 103 MCM2 Analysis of variance (ANOVA)
  2. (2003). [Alpha]-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone. doi
  3. (2001). 21 st Century molecular biology in urology. doi
  4. (1995). 5’ CpG island methylation is associated with transcriptional silencing of the tumour supressor p16/CDKN2/MTS1 in human cancer. doi
  5. (1991). A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer.
  6. A line graph of the RT-PCR results obtained when average Relative Brightness (rbu) (Appendix D Table d.18) is plotted against mean synchronisation time for PNT1A and PC-3 for MCM2. Sample Size n
  7. A line graph of the RT-PCR results obtained when average Relative Brightness (rbu) (Appendix D Table d.19) is plotted against mean synchronisation time for PNT1A and PC-3 for MCM5. Sample Size n =
  8. (2003). A new member of the MCM protein family encoded by the human MCM8 gene, located contrapodal to GD10 at chromosome band 20p12.3-13. doi
  9. (2003). A new proliferation marker, minichromosomal protein 2, is associated with tumour aggressivenenss in esophageal squamous cell carcinoma. doi
  10. (2003). A new proloferation Marker, minichromosomal maintenance protein 2, is associated with tumour aggressiveness in Esophageal squamous cell carcinoma.
  11. (2003). A novel immunohistochemistry method to estimate cell-cycle phase distribution in archial tissue: implication for prediction of outcome in colorectal cancer. doi
  12. (2003). A rotary pumping model for helicase function of MCM proteins at a distance from replication fork. doi
  13. (2004). Activation of the hedgehog pathway in advanced prostate cancer. doi
  14. (2005). Alcohol consumption and risk of prostate cancer in middle age men. doi
  15. (2001). Alcohol consumption and risk of prostate cancer: The Harvard Alumi Health Study. doi
  16. (2005). Alpha-Methylacyl-CoA Racemase (AMACR) expression in normal prostate glands and high grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer. doi
  17. (2004). Alternative spliced variants of the alpha-methylacyl-CoA racemase gene and their expression in prostate cancer. doi
  18. (2002). Analysis of minichromosomal maintenance proteins as a novel method for detection of colorectal cancer in stool. doi
  19. (1992). ATP-dependent recognition of eukaryotic origins of DNA replication by a multiprotein complex. doi
  20. (2005). Barrett's oesophagus: from metaplasia to dysplasia and cancer. doi
  21. (1999). Biochemical Charaterization of pKi67 with the identification of a Mitotic-specific assocation with hyperphosphorylation. doi
  22. (1997). Biological variation of PSA levels in serum: an evaluation of day to day physiological fluctuation in a very defined cohort of 24 patients. doi
  23. (2000). Cancer biology, 2 nd edn.
  24. (1999). Cancer facts a concise oncology text. Harwood academic publishers.
  25. (2000). Carcinogenesis in mouse and human cells: parallels and paradoxes. doi
  26. (2003). CDK- and Cdc45-dependent priming of the MCM complex on chromatin during S-phase in Xenopus egg extracts: possible activation of MCM helicase by association with doi
  27. (1996). Cell biology 2 nd edition. doi
  28. (2000). Cell cycle synchronisation of porcine foetal fibroblasts: Effects of serum deprivation and reversible cell cycle inhibitors. doi
  29. (1993). Cell proliferation in prostatic adenocarcinoma; in vitro measurements by 5-bromodeoxyuridine incorporation and proliferation cell nuclear antigen expression.
  30. (2002). Cell type-specific responses of human cells to inhibition of replication licensing. doi
  31. (1997). Characterisation of 10 new monoclonal antibodies against prostate specific antigen by analysis of affinity specificity and function in sandwich assays. doi
  32. (2002). Chromosome Replication Laboratory. London Research Institute Scientific Report,
  33. (2002). Chronic Prostatitis: epidemiology and role of infection. doi
  34. (1987). Classification of benign disease associated with prostatic pain: prostatitis or prostatodyna?
  35. (1994). Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicentered clinical trial of 6,630 men. doi
  36. (2000). Comparison of percent Free PSA, PSA Density and age-specific PSA cutoffs for prostate cancer detection and staging. doi
  37. (2003). Conditional expression of MCM7 increases tumour growth without altering DNA replication activity. doi
  38. (1987). Culture of Animal Cells, A manual of Basic techniques (2 nd Edition). Publisher Alan R doi
  39. (2006). Current prostate biopsy interpretation:criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains. doi
  40. (2005). Cytoplasmic keratin 34[beta]E12 and p63 are basal specific markers. Due to the loss of basal cells in malignancy they can be used to help distinguish BPH from adenocarcinoma
  41. (2004). DD3PCA3 RNA analysis in urine—a new perspective for detecting prostate cancer. doi
  42. (2003). Developmental role and clinical significance of hedgehog signalling. doi
  43. (2002). Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. doi
  44. (1997). Differential Effects on Growth, Cell Cycle Arrest, and Induction of Apoptosis by Resveratrol in Human Prostate Cancer Cell Lines. doi
  45. (2000). Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines. Breast cancer research and treatment 59, doi
  46. (2004). Dignostic utility of a p63/aplha-methyl-CoA racemace (P504S) cocktail in atypical foci of the prostate. doi
  47. (2002). DNA replication in eukaryotic cells. doi
  48. (2004). DNA replication regulation protein MCM7 as a marker of proliferation in prostate cancer. doi
  49. (2001). DNA-based detection of prostate cancer in urine after prostatic massage. doi
  50. (1996). Does screening for prostate cancer make sense? Scientific American.
  51. (2005). Due to the uncertainty into the usefulness of PSA this marker is under heavy debate, as some believe PSA is the best bio-marker for prostate cancer, and that screening should be applied at age 40 with annual testing (Catalona and Loeb,
  52. (1998). Emerging mechanisms of eukaryotic DNA replication initiation. doi
  53. (2003). Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection. doi
  54. (1998). Expression of ∝-Fetoprotein and prostate-specific antigen genes in several tissues and detection of mRNAs in normal circulating blood by reverse transcription-polymerase chain reaction. doi
  55. (2000). Fluorescent Methylation-specific Polymerase Chain Reaction for DNA-based Detection of Prostate Cancer in Bodily Fluids.
  56. (2003). for functional analysis of vulva intraepithelial neoplasia. doi
  57. (1995). Free and complexed prostate specific antigen (PSA): In vitro stability, epitopes mapping and development of immunofluorometric assays for specificity and sensitivity.
  58. (1998). From chimney sweeps to astronauts: cancer risks in the work place: the doi
  59. (1991). Functionally active protein C inhibitor/ plasminogen actvator-3 is secreted in seminal plasma and complexes with prostate specific antigen. doi
  60. (1989). G1 events and regulation of cell proliferation. doi
  61. (1990). GSTP1 are a family of enzymes involved in DNA protection from electrophilic metabolites of carcinogens and reactive oxygen species by conjugating chemically reactive electrophiles to glutathione (Coles & Ketterer
  62. (2005). Hedgehog signalling in prostate regeneration: Neoplasia and metastasis. doi
  63. (2000). Helix Destabilising Model Where helicase binds to the directly melt duplex of the DNA.
  64. (2002). Histology and cell biology. An introduction to pathology. Sperm transport and maturation, doi
  65. (1996). How cancer spreads. doi
  66. (2002). How Many Mutations in a Cancer? doi
  67. (1998). Human Minichromosome Maintenance Proteins and Human Origin Recognition Complex 2 Protein on Chromatin. doi
  68. (1986). Human prostate specific antigen: structural and functional similarities with serine proteases. doi
  69. (1996). Human replication proteins hcdc21, hcdc46 and P1mcm3 bind chromatin uniformly before S-phase and are displaced localy during DNA replication.
  70. (2002). Immortalisation and transformation revisited. doi
  71. (1999). Immunoassay for urothelial cancers that detects DNA replication protein MCM5 in urine. doi
  72. (2005). Immunohistochemistry markers in the diagnosis of prostate cancer. doi
  73. (2004). Improved biomarkers for prostate cancer: A definite need. doi
  74. (1999). Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. doi
  75. (2004). Inhibition of prostate cancer cell colony formation by flavonoid Quercetin correlates with modulation of specific regulatory genes. doi
  76. (2001). Interaction between two Catalytically Distinct MCM subgroups are essential for Coordinated ATP Hydrolsis and DNA Replication. doi
  77. Interrelation between western type cancers and non-western type cancers as regards their risk variation in time and space. 11 Nutrition and cancer risk.
  78. Is the MCM2-7 complex the eukaryotic DNA replication fork helicase? doi
  79. (1998). It is interesting to also consider what may have been found if the LNCaP cells were included in this study. For these, it is possible that a greater increase in PSA expression may have been detected. This is because previous studies such as Sun, et al
  80. L Figure 5.14. Ethidium bromide stained gel showing MCM5 RT-PCR (500bp bands visible) for RNA extracted from 35 urine pellets.
  81. (2003). Lead times and overdetection due to prostate specific antigen screening: Estimates from the European Randamised Study of Screening for Prostate Cancer. doi
  82. (1997). Life the science of biology 5 th edition. Sinauer associates inc, WH freeman and company.
  83. (1996). Making headway against cancer. Scientific American. doi
  84. (2003). Mammalian MCM2/4/6/7 complex forms a toroidal structure. doi
  85. (2001). MCM2 is an independent predictor of survival in patients with non-small cell lung cancer. doi
  86. (2002). MCM2-7 complexes bind chromatin in a distributed pattern surrounding ORC in Xenopus egg extracts. doi
  87. (2003). MCM4, 6, 7 Uses a “Pump in Ring” Mechanism to Unwind DNA by Steric Exclusion and Actively Translocate along a Duplex. doi
  88. (1991). Measurement of prostate-specific antigen serum as a screening test for prostate cancer. doi
  89. (2003). Mechanism illustrated is the Pump in model. Adapted using Laskey and Madine
  90. (2002). Minichromosomal maintenance protein 2 expression in normal kidney and renal cell carcinoma: Relationship to tumour dormancy and potential clinical utility.
  91. (1999). Minichromosomal maintenance proteins as biological markers of dysplasia and malignancy.
  92. (2002). Minichromosome maintenance protein MCM7 is adirect target of the MYCN transcription factor in neuroblastom.
  93. (2001). Minichromosome maintenance proteins 2 expression in prostate: Characterisation and association outcome after therapy for cancer.
  94. (1993). Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TCF-ß and a proteolytic modulation of cell adhesion receptors. doi
  95. (1987). Modulation of p53 protein expression during cellular transformation with simian virus 40. Mol Cell bol
  96. (1999). Molecular detection of prostate cells in ejaculate and urethral washings in men with suspected prostate cancer. doi
  97. (1997). Molecular forms of prostate specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for the early detection and staging of prostate cancer. doi
  98. (1995). Molecular forms of prostate specific antigen and human kallikreins gene family: A new era. doi
  99. (1996). Mouse MCM proteins: complex formation and transportation to the Nucleus. Genes to Cells doi
  100. (1984). Mutants of S. cerevisiae defective in the maintenance of minichromosomes.
  101. (1995). New diagnostic applications and physioloigcal functions of prostate specific antigen. doi
  102. (2005). New insight in telomerase and telomeric proteins and their clinical application to urological cancer. doi
  103. (2001). Non-invasive methods to detect prostate cancer.
  104. (2005). Noninvasive Detection of Prostate Cancer by Quantitative Analysis of Telomerase Activity. doi
  105. (2001). Not only this, but some believe PSA is produced mainly by the prostatic epithelium, with only low concentrations in endometrium, breast tissue, adrenal, renal and female
  106. (2002). Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. doi
  107. of samples with No relative brightness Reading No. of samples with a relative brightness Reading Percent expressing relative brightness reading Mean relative brightness Reading (Total relative brightness/total No. of samples) doi
  108. (2001). Oncology. Oxford handbook of clinical doi
  109. (2000). Overview of health benefits of fruits and vegatable consumption for the dietetics professional. doi
  110. (1997). Overview of in vitro cell culture technologies and pharmoco-toxiological application.
  111. (2004). Overview of Overactive Bladder, Prostatitis, and Lower Urinary Tract Symptoms for the Primary Care Physicans. Reviews in
  112. (2002). Overweight, obesity and cancer risk. doi
  113. (2002). Patterns and trends in prostate cancer incidence, survival prevalence and mortality. Part 1: international comparisons. doi
  114. (2002). Patterns and trends in prostate cancer incidence, survival prevalence and mortality. Part 11: individual countries. doi
  115. (2002). Preoperative serum prostate specific antigen levels between 2 and 22ng./ml. Correlate 184poorly with postradical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. doi
  116. (2003). Prognostic value of MCM immunoreactivity in stage T1 transitional cell carcinoma of the bladder. doi
  117. (1998). Prostate and bladder cancer screening. doi
  118. (1997). Prostate cancer detection in men with serum PSA concentration of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurement. doi
  119. (2000). Prostate Cancer. The role of transrectal ultrasound and its impact on cancer detection and management. doi
  120. (1997). Prostate specific antigen (PSA) in breast and ovarian cancer.
  121. (1992). Prostate specific antigen density: a means of distinguising benign prostatic hypertrophy and prostate cancer.
  122. (1997). Prostate specific antigen in men born with bladder exstrophy. doi
  123. (1989). Prostate Specific antigen: Its role in early detection, staging and monitoring of prostate carcinoma. doi
  124. (1992). Prostate-Specific antigen is an insulin-like growth factor binding protien-3 protease found in seminal plasmia. doi
  125. (2000). Prostate-Specific Antigen Synthesis and Secretion by Human Placenta: A Physiological Kallikrein Source during Pregancy. doi
  126. (1999). Prostate-specific antigen: advances and challenges. doi
  127. (1998). Prostate-specific antigen: its usefulness in clinical medicine. doi
  128. (2004). Prostate-Specific Antigen. doi
  129. (2005). Prostatic Intraepithelial Neoplasia: An overview. doi
  130. (2001). Proteomic approaches to biomarker discovery in prostate and bladder cancers. doi
  131. (2000). Pump in Ring Model Where single stranded DNA is pulled through the central cavity unwinding the DNA. Kaplan, et al
  132. (1979). Purification of a human prostate specific antigen.
  133. (2006). Quantification of immunohistochemistry -issues concerning methods, utility and semiquantitative assessment ll. doi
  134. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. doi
  135. (1998). Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. doi
  136. (1999). Reduced dosage of a single fission yeast MCM protein causes genetic instability and S phase delay.
  137. (1996). Regulatory Roles of the Nuclear Envelope. doi
  138. (2002). Replication licensing – defining the proliferative state? Trends in cell biology. doi
  139. (1993). Risk factors for prostate and testicular cancer. doi
  140. (1999). Robbins Pathologic basis of disease 6 th Edition. WB Saunders Company.
  141. RT-PCR results obtained when average Relative Brightness (rbu) (Appendix D table d.12) is plotted against percent confluence for PNT1A and PC-3 for MCM5. Samples Size for each cell line and confluence
  142. (1999). Saying a firm ‘no’ to DNA re-replication.
  143. (1999). Serum prostate-specific antigen concentration is as powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. doi
  144. (1992). Serum specific antigen in the community based population of healthy men: establishment of age specific reference ranges. doi
  145. (2003). Sexual factors and prostate cancer. doi
  146. (1977). Skin-tumor-initiating ability of benzo(a)pyrene-7,8-diol-9,10-epoxide (anti) when applied topically in tetrahydrofuran. doi
  147. (2004). Society and National Comprehensive Cancer Network (NCCN). doi
  148. (2005). Sonic hedgehog signalling in basal cell carcinoma. doi
  149. (2004). Stability Although the MCMs play an important role in replication, this is not their only role as it is estimated that the MCMs are 40-100 fold more abundant than the origins require (Bailis and Forsburg,
  150. (1994). stated that the basal layer is the actively proliferating compartment of the prostate gland in normal tissue, while Carroll, 106 et al
  151. (2000). Structure and Function of Hexameric Helicases. doi
  152. (2000). Subcellular localisation and physiological role of alpha-methyacyl-CoA racemase.
  153. (1990). Subcellular localisation of yeast CDC46 varies with the cell cycle. doi
  154. (2001). Switching and signalling at the telomere. doi
  155. (1996). Telomerase and cancer: revisiting the telomere hypothesis. doi
  156. (2001). that found for adenocarcinoma staining of MCM2 ranges between 1-41%.
  157. (2001). The biosynthesis of prostate-specific antigen in no prostatic cell lines. doi
  158. (1989). The Cell Cycle. doi
  159. (1976). The Clonal Evolutions of tumour cell populations. doi
  160. (2002). The effect of diet on risk of cancer. doi
  161. (2005). The Era is Not Over for Prostate Cancer. doi
  162. (1997). The focus of “atypical glads, suspicious for malignancy” in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice.
  163. (2000). The hallmarks of Cancer. doi
  164. (1994). The proliferative function of basal cells in the normal and hyperplastic human prostate. doi
  165. (1999). The Prostate and Seminal Vesicles. Diagnostic Surgical Pathology.
  166. (1988). The prostate book, published by Peneguin books Canada Ltd.
  167. (2004). The prostate specific antigen ERA in the United States is over for prostate cancer: What happened in the last 20 years? doi
  168. (2004). The Regulation Association of doi
  169. (1990). The role of glutathione and glutathione transferase in chemical carcinogenesis. doi
  170. (2000). The role of promotion in Carcinogenesis from protracted high-LET exposure. doi
  171. (2000). The role of prostate specific antigen measurement in the detection and management of prostate cancer. doi
  172. (1999). The second explanation supports the suggestion that Ki67 is not accurate at indicating proliferative state. For instance, Freeman, et al
  173. (1999). The study of PSA gene expression on urogenital cell lines. doi
  174. (2001). The use of telomerase activity for the detection of prostate cancer cells after prostatic massage. doi
  175. (2001). The value of current diagnostic tests in prostate cancer screening. doi
  176. (2003). Total, free and complexed PSA and hK2 for early detection of prostate cancer. Cover story.
  177. (2002). Towards the molecular diagnosis of ladder and colorectal cancer: anaylsis of CD44 exon splicing thesis. Thesis
  178. (1983). Triethylenemelamine: An initiator of twostage carcinogenesis in mouse skin which lacks the potential of a complete carcinogen. doi
  179. (2001). Two genetic hits (more or less) to cancer.
  180. (2004). uPM3, a new molecular urine test for the detection of prostate cancer. doi
  181. (2005). Using an AMACR (P504S)/34βE12/p63 Cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens, doi
  182. (2003). Viruses and cancer: lessons from the human polyomarvirus JCV. doi
  183. (2000). Wedge Model Where helicase binds to one strand and drives the DNA apart.
  184. (1992). Western blotting using the ProtoBlot® II AP System with stabilized substrate.
  185. (1996). What causes cancer?. Scientific American. doi
  186. (1996). Wheater’s Basic Histopathology a colour atlas and text – 3 rd Edition.
  187. (1998). Xenopus Cdc45-dependent loading of DNA polymerase aplha onto chromatin under the control of S-phase Cdk. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.